Parameters predicting mortality in antifibrotic-treated IPF patients: mMRC, CPI, TLCO, FVC, GAP

BACKGROUND: Idiopathic pulmonary fibrosis(IPF) continues to be a fatal disease despite the use of antifibrotic therapy. There is limited data on the prognostic importance of parameters predicting mortality. We aimed to identify independent mortality predictors in antifibrotic-treated IPF patients. METHODS: With ethics committee approval, IPF patients receiving consecutively antifibrotic treatment between 1 January 2013-01.01.2023 at Izmir Dr Suat Seren Chest Disease and Surgery Training and Research Hospital were retrospectively screened. The clinical-demographic-radiologic data were recorded. Cox regression and Kaplan-Meier analyses explored associations with mortality; receiver-operating-characteristic (ROC) curves defined optimal cutoffs. RESULTS: = 0.048). CONCLUSION: Patients with symptom progression, mMRC >2, presence of honeycombing on radiological imaging, FVC ≤71%, and CPI >49.2 have a higher risk of mortality and should be referred for pulmonary rehabilitation and lung transplantation evaluation at an early stage.

Authors

Institutions

Publication Details

Journal
Biomarkers in Medicine
Published
2026-09-25
DOI
https://doi.org/10.1080/17520363.2026.2737283
Primary Topic
Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
article

Parameters predicting mortality in antifibrotic-treated IPF patients: mMRC, CPI, TLCO, FVC, GAP

Enver Yalnız, Gülistan Karadeniz, Fatma Demirci Üçsular, Sevda Aras
Biomarkers in Medicine
Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
article

Parameters predicting mortality in antifibrotic-treated IPF patients: mMRC, CPI, TLCO, FVC, GAP

Enver Yalnız, Gülistan Karadeniz, Fatma Demirci Üçsular, Sevda Aras
article en

Abstract

BACKGROUND: Idiopathic pulmonary fibrosis(IPF) continues to be a fatal disease despite the use of antifibrotic therapy. There is limited data on the prognostic importance of parameters predicting mortality. We aimed to identify independent mortality predictors in antifibrotic-treated IPF patients. METHODS: With ethics committee approval, IPF patients receiving consecutively antifibrotic treatment between 1 January 2013-01.01.2023 at Izmir Dr Suat Seren Chest Disease and Surgery Training and Research Hospital were retrospectively screened. The clinical-demographic-radiologic data were recorded. Cox regression and Kaplan-Meier analyses explored associations with mortality; receiver-operating-characteristic (ROC) curves defined optimal cutoffs. RESULTS: = 0.048). CONCLUSION: Patients with symptom progression, mMRC >2, presence of honeycombing on radiological imaging, FVC ≤71%, and CPI >49.2 have a higher risk of mortality and should be referred for pulmonary rehabilitation and lung transplantation evaluation at an early stage.

Biomarkers in Medicine
Izmir University (TR), Sağlık Bilimleri Üniversitesi (TR)
Good health and well-being
Openalex Percentile: Top 12%
Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Parameters predicting mortality in antifibrotic-treated IPF patients: mMRC, CPI, TLCO, FVC, GAP — Enver Yalnız, Gülistan Karadeniz, et al. · Biomarkers in Medicine (2026) | TGRS Research Map | TGRS